

November 12, 2024

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

**The National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai 400 051

Scrip Code: **544184**

Trading Symbol: **BOROSCI**

Dear Sir(s),

**Sub: Intimation of the outcome of the Board Meeting under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

---

Further to our letter dated November 5, 2024, we hereby inform you that the Board of Directors of the Company at their meeting held today i.e. November 12, 2024, have, *inter alia*, considered and approved the following:

**1. Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2024**

The Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2024 along with an extract to be published in newspapers and the Limited Review Reports of the Statutory Auditor thereon are enclosed herewith and also available on the Company's website at [www.borosilscientific.com](http://www.borosilscientific.com).

**2. Recommendation for re-appointment of Independent Directors**

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have recommended the following for approval of the Members of the Company:

- Re-appointment of Mr. Kewal Kundanlal Handa (DIN: 00056826) as an Independent Director of the Company for the second term of 5 (five) consecutive years i.e. from March 1, 2025 upto February 28, 2030; and
- Re-appointment of Mrs. Anupa Rajiv Sahney (DIN: 00341721) as an Independent Director of the Company for the second term of 5 (five) consecutive years i.e. from March 1, 2025 upto February 28, 2030.

Brief profile and other details of **Mr. Kewal Kundanlal Handa and Mrs. Anupa Rajiv Sahney**, as required under Regulation 30 of the Listing Regulations read with the Securities and Exchange Board of India ('SEBI') Master Circular dated July 11, 2023 and SEBI Circular dated July 13, 2023, are given in the **Annexure A**.

The meeting of the Board of Directors commenced at 3:30 p.m. (IST) and concluded at 4:35 p.m. (IST).

Thanking You,

Yours faithfully,

For **Borosil Scientific Limited**

**Sanjay Gupta**  
**Company Secretary & Compliance Officer**  
**ICSI Membership No.: A24641**

Encl: as above

### Annexure A

#### Re-appointment of Mr. Kewal Kundanlal Handa (DIN: 00056826) and Mrs. Anupa Rajiv Sahney (DIN: 00341721) as Independent Directors of the Company

Sr. No.	Particulars	Mr. Kewal Kundanlal Handa	Mrs. Anupa Rajiv Sahney
1	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment of Mr. Kewal Kundanlal Handa (DIN: 00056826) as an Independent Director of the Company for the second term of 5 (five) consecutive years.	Re-appointment of Mrs. Anupa Rajiv Sahney (DIN: 00341721) as an Independent Director of the Company for the second term of 5 (five) consecutive years.
2	Date of <del>appointment / re-appointment / cessation</del> (as applicable) & term of <del>appointment / re-appointment</del>	March 1, 2025  Re-appointment for the second term of 5 (five) consecutive years commencing from March 1, 2025 upto February 28, 2030, subject to approval of the Members of the Company.	
3	Brief profile (in case of appointment)	<p><b>Mr. Kewal Kundanlal Handa</b></p> <p>Mr. Kewal Kundanlal Handa is a qualified Management Accountant and Company Secretary along with a master's degree in commerce. He has completed the Pfizer Leadership Development Program from Harvard University and the Senior Management Development Program from IIM, Ahmedabad. He has also completed a certificate course on Marketing Strategy from Columbia Business School, New York.</p> <p>Mr. Kewal Kundanlal Handa has a diverse experience in Finance, Commercial, Strategy, Business Development, Mergers &amp; Acquisitions, Banking and Corporate Affairs. He is also</p>	<p><b>Mrs. Anupa Rajiv Sahney</b></p> <p>Mrs. Anupa Rajiv Sahney, a member of the ICAEW, has a strong academic interest in Indian Art History. She serves on the Advisory Boards of the Harvard South Asia Institute, Harvard School of Public Health - India Research Centre, and BALCO Medical Centre. Having founded Origami Consultants, Mrs. Sahney began her consulting career with McKinsey &amp; Co. in 1993, advising international companies like AIG and Capital One.</p>

		<p>experienced in sectors like Engineering, Consumer and Project Finance in various companies.</p> <p>He was the Managing Director of Pfizer Limited. He was also the Non-Executive Chairman of Union Bank of India. Mr. Handa was awarded the 'India CFO 2004 – Excellence in Finance in an MNC' by the International Market – Assessment Group, the Bharat Shiromani Award in 2007 and the Pharma Leaders - Pharma Professional of the Year 2010.</p>	
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Kewal Kundanlal Handa is not related to any Director of the Company.	Mrs. Anupa Rajiv Sahney is not related to any Director of the Company.
5	Information required pursuant to BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/ CML/2018/24 dated June 20, 2018	Mr. Kewal Kundanlal Handa is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.	Mrs. Anupa Rajiv Sahney is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.

**Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,

**The Board of Directors of  
Borosil Scientific Limited  
(Formerly Known as Klass Pack Limited)**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Borosil Scientific Limited (Formerly Known as Klass Pack Limited)** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together refer to as "the Group") for the quarter and half year ended 30<sup>th</sup> September, 2024 ("the statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ("the Listing Regulation"), as amended.
2. This statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





We also performed procedures in accordance with the circular no. CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

4. The statement includes the results of its subsidiary Goel Scientific Glass Works Limited.
5. Based on our review conducted as above and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial result includes the interim financial results of 1 subsidiary, whose interim financial results reflect total assets of Rs. 4,584.93 Lakhs as at 30<sup>th</sup> September, 2024, total revenue of Rs. 1,652.14 Lakhs and Rs. 2,774.52 Lakhs, total net profit/(loss) after tax of Rs. 150.31 Lakhs and Rs. 17.74 Lakhs and total comprehensive income of Rs. 149.52 Lakhs and Rs. 16.15 Lakhs for the quarter ended 30<sup>th</sup> September, 2024 and for the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024 respectively, and cash inflow (net) of Rs. 24.55 Lakhs for the period from 1<sup>st</sup> April, 2024 to 30<sup>th</sup> September, 2024, as considered in the unaudited consolidated financial results. The interim financial results of the above subsidiary have been reviewed by other auditor, whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to amount and disclosures included in respect of that subsidiary is based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above.



Our conclusion on the statement is not modified in respect of the above matter with respect to our reliance on the work done and the report of other auditor.

**For Chaturvedi & Shah LLP**

Chartered Accountants

Registration No. 101720W/W100355

**Anuj Bhatia**

Partner

Membership No. 122179

UDIN No: 24122179BKFB JW4181



Place: Mumbai

Date: 12<sup>th</sup> November 2024

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024**

(Rs. in lakhs except as stated)

S. No.	Particulars	Consolidated					
		Quarter ended			Half Year Ended		Year ended
		(30/09/2024)	(30/06/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(31/03/2024)
I.	<b>Income:</b>						
	Revenue From Operations	10,261.43	10,419.73	9,196.86	20,681.16	17,951.13	39,457.84
	Other Income	194.60	215.60	144.40	410.20	255.87	542.40
	<b>Total Income (I)</b>	<b>10,456.03</b>	<b>10,635.33</b>	<b>9,341.26</b>	<b>21,091.36</b>	<b>18,207.00</b>	<b>40,000.24</b>
II.	<b>Expenses:</b>						
	Cost of Materials Consumed	3,344.07	3,409.04	3,098.43	6,753.11	6,100.21	12,847.10
	Purchases of Stock-in-Trade	349.86	210.53	426.97	560.39	539.11	1,549.42
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(244.88)	110.86	(363.32)	(134.02)	(142.66)	76.69
	Employee Benefits Expense	1,855.85	1,923.30	2,026.96	3,779.15	3,810.62	7,523.70
	Finance Costs	35.53	39.77	73.13	75.30	148.98	270.17
	Depreciation and Amortization Expense	462.59	456.71	385.29	919.30	749.87	1,644.87
	Other Expenses	3,411.99	3,782.77	3,060.88	7,194.76	6,125.71	12,933.18
	<b>Total Expenses (II)</b>	<b>9,215.01</b>	<b>9,932.98</b>	<b>8,708.34</b>	<b>19,147.99</b>	<b>17,331.84</b>	<b>36,845.13</b>
III.	<b>Profit before share of profit in associate, exceptional items and tax (I - II)</b>	<b>1,241.02</b>	<b>702.35</b>	<b>632.92</b>	<b>1,943.37</b>	<b>875.16</b>	<b>3,155.11</b>
IV.	Share of profit in associates	-	-	-	-	-	-
V.	<b>Profit before Exceptional Items and tax (III + IV)</b>	<b>1,241.02</b>	<b>702.35</b>	<b>632.92</b>	<b>1,943.37</b>	<b>875.16</b>	<b>3,155.11</b>
VI.	Exceptional Items	-	-	-	-	-	-
VII.	<b>Profit Before Tax (V - VI)</b>	<b>1,241.02</b>	<b>702.35</b>	<b>632.92</b>	<b>1,943.37</b>	<b>875.16</b>	<b>3,155.11</b>
VIII.	<b>Tax Expense:</b>						
	(1) Current Tax	315.79	128.68	297.01	444.47	409.67	1,310.54
	(2) Deferred Tax	44.79	71.39	(168.67)	116.18	(367.68)	(503.58)
	<b>Total Tax Expenses</b>	<b>360.58</b>	<b>200.07</b>	<b>128.34</b>	<b>560.65</b>	<b>41.99</b>	<b>806.96</b>
IX.	<b>Profit for the Period / Year (VII - VIII)</b>	<b>880.44</b>	<b>502.28</b>	<b>504.58</b>	<b>1,382.72</b>	<b>833.17</b>	<b>2,348.15</b>
X.	<b>Other Comprehensive Income (OCI)</b>						
	<b>Items that will not be reclassified to profit or loss:</b>						
	a) Re-measurement gains / (losses) on defined benefit plans	(6.67)	(5.85)	(8.22)	(12.52)	(47.85)	(27.59)
	b) Income tax effect on above	1.69	1.47	2.07	3.16	12.05	6.95
	<b>Total Other Comprehensive Income</b>	<b>(4.98)</b>	<b>(4.38)</b>	<b>(6.15)</b>	<b>(9.36)</b>	<b>(35.80)</b>	<b>(20.64)</b>
XI.	<b>Total Comprehensive Income for the period / year (IX + X)</b>	<b>875.46</b>	<b>497.90</b>	<b>498.43</b>	<b>1,373.36</b>	<b>797.37</b>	<b>2,327.51</b>
XII.	<b>Profit attributable to:</b>						
	Owners of the Company	879.36	503.68	514.65	1,383.04	852.19	2,355.86
	Non-controlling interest	1.08	(1.40)	(10.07)	(0.32)	(19.02)	(7.71)
XIII.	<b>Other Comprehensive Income attributable to:</b>						
	Owners of the Company	(4.97)	(4.37)	(5.99)	(9.34)	(35.64)	(20.49)
	Non-controlling interest	(0.01)	(0.01)	(0.16)	(0.02)	(0.16)	(0.15)
XIV.	<b>Total Comprehensive Income attributable to:</b>						
	Owners of the Company	874.39	499.31	508.66	1,373.70	816.55	2,335.37
	Non-controlling interest	1.07	(1.41)	(10.23)	(0.34)	(19.18)	(7.86)
XV.	<b>Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up)(Refer Note 2)</b>	<b>888.62</b>	<b>887.96</b>	<b>28.60</b>	<b>888.62</b>	<b>28.60</b>	<b>887.96</b>
XVI.	<b>Share Capital Pending Issuance (Refer Note 3)</b>	<b>-</b>	<b>-</b>	<b>859.04</b>	<b>-</b>	<b>859.04</b>	<b>-</b>
XVII.	<b>Other Equity excluding Revaluation Reserve</b>						<b>35,603.42</b>
XVIII.	<b>Earning per equity share (in Rs.) (Face value of Re. 1/- each) (Refer Note 3)</b>						
	Basic (Not Annualised)*	0.99 *	0.57 *	0.58 *	1.56 *	0.96 *	2.65
	Diluted (Not Annualised)*	0.99 *	0.57 *	0.58 *	1.56 *	0.96 *	2.65





**BOROSIL SCIENTIFIC LIMITED**  
(FORMERLY KNOWN AS KLASSE PACK LIMITED)

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024

(Rs. in lakhs)

S. No.	Particulars	Consolidated					
		Quarter ended			Half Year Ended		Year ended
		(30/09/2024)	(30/06/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(31/03/2024)
1	<b>Segment Revenue :</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	7,104.07	7,021.68	5,826.25	14,125.75	11,493.90	26,473.31
	b. Glassware	3,041.44	3,306.61	3,299.76	6,348.05	6,316.59	12,635.06
	c. Others	115.92	91.44	70.85	207.36	140.64	349.47
	<b>Total</b>	<b>10,261.43</b>	<b>10,419.73</b>	<b>9,196.86</b>	<b>20,681.16</b>	<b>17,951.13</b>	<b>39,457.84</b>
	Less : Inter Segment Revenue	-	-	-	-	-	-
	<b>Revenue from operations</b>	<b>10,261.43</b>	<b>10,419.73</b>	<b>9,196.86</b>	<b>20,681.16</b>	<b>17,951.13</b>	<b>39,457.84</b>
2	<b>Segment Results (Profit /(Loss) before tax and non-controlling interests):</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	1,836.02	1,389.83	795.51	3,225.85	1,519.62	4,669.10
	b. Glassware	(155.07)	(293.16)	(78.31)	(448.23)	(482.02)	(815.90)
	c. Others	69.84	35.20	26.22	105.04	49.97	144.58
	<b>Total</b>	<b>1,750.79</b>	<b>1,131.87</b>	<b>743.42</b>	<b>2,882.66</b>	<b>1,087.57</b>	<b>3,997.78</b>
	Less:- Finance Cost	35.53	39.77	73.13	75.30	148.98	270.17
	Less:- Other unallocable expenditure (net of income)	474.24	389.75	37.37	863.99	63.43	572.50
	<b>Profit before Tax</b>	<b>1,241.02</b>	<b>702.35</b>	<b>632.92</b>	<b>1,943.37</b>	<b>875.16</b>	<b>3,155.11</b>
3	<b>Segment Assets</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	20,553.54	19,256.91	19,207.10	20,553.54	19,207.10	19,619.39
	b. Glassware	10,867.83	11,361.26	10,240.76	10,867.83	10,240.76	11,463.54
	c. Others	220.49	190.44	282.26	220.49	282.26	280.22
	d. Un-allocated	17,336.55	17,498.04	16,760.82	17,336.55	16,760.82	17,955.34
	<b>Total</b>	<b>48,978.41</b>	<b>48,306.65</b>	<b>46,490.94</b>	<b>48,978.41</b>	<b>46,490.94</b>	<b>49,318.49</b>
4	<b>Segment Liabilities</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	5,205.45	5,761.61	5,012.19	5,205.45	5,012.19	6,203.32
	b. Glassware	1,975.05	2,195.19	1,978.24	1,975.05	1,978.24	2,702.41
	c. Others	23.86	34.20	19.12	23.86	19.12	35.02
	d. Un-allocated	2,689.35	2,198.24	3,379.04	2,689.35	3,379.04	2,758.23
	<b>Total</b>	<b>9,893.71</b>	<b>10,189.24</b>	<b>10,388.59</b>	<b>9,893.71</b>	<b>10,388.59</b>	<b>11,698.98</b>

**Note :**

The responsibility of identifying reportable segments lies with the Chief Operating Decision Maker (CODM) as per the Indian Accounting Standard 108 "Operating Segments". Considering the categories of business operations conducted and based on the future business plans, during the period, the CODM has adopted a new enhanced approach towards monitoring and allocation of the resources to the business, accordingly during the quarter and half year ended, the Group has identified two segments, namely "Scientific – Laboratory Glass & equipment and Process System" and "Glassware". The figures for the previous periods / year have been regrouped to make them comparable with those of the current period.

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Group has reported "Segment information", as described below:

**Scientific – Laboratory Glass & equipment and Process System:-** Comprising of items used in laboratories, production floor and research and development

**Glassware:-** pharmaceutical primary packaging and domestic glassware items

**Others :-** Comprising of Filter Paper etc.

**Unallocated:-** Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.



**BOROSIL SCIENTIFIC LIMITED**  
(FORMERLY KNOWN AS KLASS PACK LIMITED)

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

(Rs. in lakhs)

Particulars	Consolidated	
	As at	As at
	(30/09/2024)	(31/03/2024)
<b>I. ASSETS</b>		
<b>1 Non-current Assets</b>		
(a) Property, Plant and Equipment	11,705.16	12,379.45
(b) Capital work-in-progress	371.55	82.63
(c) Goodwill on Amalgamation	6,219.37	6,219.37
(d) Other Intangible assets	560.23	624.77
(e) Intangible assets under development	27.88	20.78
(f) Financial Assets		
(i) Investments	1.31	1.31
(ii) Loans	7.46	7.00
(iii) Others	196.99	190.34
(g) Deferred Tax Assets (net)	458.60	487.09
(h) Non Current Tax Assets (net)	193.02	55.62
(i) Other non current assets	275.17	194.19
<b>Total non current assets</b>	<b>20,016.74</b>	<b>20,262.55</b>
<b>2 Current Assets</b>		
(a) Inventories	10,101.37	9,686.15
(b) Financial Assets		
(i) Investments	614.96	-
(ii) Trade Receivables	5,827.57	6,147.99
(iii) Cash and cash equivalents	536.70	1,212.87
(iv) Bank Balances other than (iii) above	176.02	170.75
(v) Loans	24.20	24.49
(vi) Others	9,738.73	10,324.17
(c) Current Tax Assets (net)	9.40	9.40
(d) Other current assets	1,932.72	1,480.12
<b>Total current assets</b>	<b>28,961.67</b>	<b>29,055.94</b>
<b>TOTAL ASSETS</b>	<b>48,978.41</b>	<b>49,318.49</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	888.62	887.96
(b) Share Application Money	16.53	-
(c) Other Equity	38,150.05	36,701.71
<b>Equity attributable to the owners</b>	<b>39,055.20</b>	<b>37,589.67</b>
Non-controlling interest	29.50	29.84
<b>Total equity</b>	<b>39,084.70</b>	<b>37,619.51</b>
<b>LIABILITIES</b>		
<b>1 Non current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	369.04	449.50
(ii) Lease Liabilities	-	30.98
(b) Provisions	496.50	475.37
(c) Deferred Tax Liabilities (net)	828.37	743.84
<b>Total non current liabilities</b>	<b>1,693.91</b>	<b>1,699.69</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,306.73	1,208.43
(ii) Lease Liabilities	75.94	88.15
(iii) Trade Payables		
A) Total outstanding dues of micro and small enterprises	887.37	894.61
B) Total outstanding dues of creditors other than micro and small	1,873.35	3,139.57
(iv) Other Financial Liabilities	2,236.57	2,246.79
(b) Other current liabilities	816.79	1,293.62
(c) Provisions	965.88	960.34
(d) Current Tax Liabilities (net)	37.17	167.78
<b>Total current liabilities</b>	<b>8,199.80</b>	<b>9,999.29</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>48,978.41</b>	<b>49,318.49</b>



**BOROSIL SCIENTIFIC LIMITED**  
**(FORMERLY KNOWN AS KLASS PACK LIMITED)**

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

Particulars	(Rs. In Lakhs)	
	For the Half Year Ended (30/09/2024)	For the Half Year Ended (30/09/2023)
<b>A. Cash Flow from Operating Activities</b>		
Profit Before Tax as per Statement of Profit and Loss	1,943.37	875.16
Adjusted for :		
Depreciation and Amortisation Expense	919.30	749.87
Loss / (Gain) on Foreign Currency Transactions (net)	(8.85)	(21.65)
Loss / (Gain) on Financial Instruments measured at fair value through profit or loss (net)	(1.51)	-
Loss / (Gain) on Sale of Investments (net)	(13.45)	(24.53)
Interest Income	(188.46)	(15.81)
Loss / (Gain) on Sale / discarding of Property, Plant and Equipment (net)	7.43	2.27
Share Based Payment Expense	15.31	29.41
Finance Costs	75.30	148.98
Sundry Balances / Excess Provision Written Back (net)	0.30	(0.01)
Provision / (Reversal) for Credit Impaired / Doubtful Advances (net)	(1.92)	0.38
<b>Operating Profit before Working Capital Changes</b>	<b>2,746.82</b>	<b>1,744.07</b>
Adjusted for :		
Trade and Other Receivables	616.88	(591.22)
Inventories	(415.22)	611.15
Trade and Other Payables	(1,724.61)	(20.31)
<b>Cash generated from operations</b>	<b>1,223.87</b>	<b>1,743.69</b>
Direct Taxes Paid (net)	(712.48)	(697.02)
<b>Net Cash From / (Used in) Operating Activities</b>	<b>511.39</b>	<b>1,046.67</b>
<b>B. Cash Flow from Investing Activities</b>		
Purchase of Property, Plant and Equipment and Intangible Assets	(598.74)	(545.93)
Sale of Property, Plant and Equipment (net)	13.31	0.28
Purchase of Non Current Investments	(2,600.00)	(2,247.99)
Sale of Investments	2,000.00	3,264.84
Income / Interest on Investment/Loans	21.53	18.62
<b>Net Cash From / (Used in) Investing Activities</b>	<b>(1,163.90)</b>	<b>489.82</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds of Equity Share Capital	91.83	-
Proceeds of Non-current Borrowings	-	125.18
Repayment of Non-current Borrowings	(136.42)	(139.83)
Movement in Current Borrowings (net)	154.26	(1,027.36)
Lease Payments	(47.26)	(47.25)
Margin Money (net)	(6.58)	(5.17)
Interest Paid	(79.50)	(139.31)
<b>Net Cash From / (Used in) Financing Activities</b>	<b>(23.67)</b>	<b>(1,233.74)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(676.18)</b>	<b>302.75</b>
<b>Opening Balance of Cash and Cash Equivalents</b>	<b>1,212.87</b>	<b>48.92</b>
On Account of Acquisition	-	8.21
Unrealised Gain/(loss) on Foreign Currency Transactions (net)	0.04	0.08
<b>Opening Balance of Cash and Cash Equivalents</b>	<b>1,212.83</b>	<b>57.05</b>
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>536.70</b>	<b>359.80</b>
Unrealised Gain/(loss) on Foreign Currency Transactions (net)	0.05	-
<b>Closing Balance of Cash and Cash Equivalents</b>	<b>536.65</b>	<b>359.80</b>





**Notes on Unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2024:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12th November, 2024. The Statutory Auditor of the Company has carried out a Limited Review of the above results.
2. Pursuant to exercise of the options issued under "Borosil Scientific Limited -Special Purpose Employee Stock Option Plan 2023", during the quarter and half year ended 30th September, 2024, the Company has made allotment of 65,791 Equity Shares of the face value of Re. 1/- each, which has resulted into increase of paid up Equity Share Capital by Rs. 0.66 lakhs and Securities Premium by Rs. 74.64 lakhs.
3. Share Capital Pending Issuance for the quarter and half year ended 30th September, 2023 represents shares to be issued to the shareholders of the Demerged Company pursuant to the Composite Scheme of Arrangement approved by the National Company Law Tribunal ("NCLT"), Mumbai vide its order dated 2nd November, 2023 ("the Scheme") and accordingly the same had been considered while calculating Earnings Per Share (EPS) as per Indian Accounting Standard (Ind AS) 33 "Earnings Per Share".
4. The figures for the corresponding previous period/year have been rearranged/regrouped wherever necessary. The figures for the quarter and half year ended 30th September, 2023 have been restated by the management pursuant to the Scheme, to make them comparable.

**For Borosil Scientific Limited  
(Formerly Known as Klass Pack Limited)**



**Vinayak Patankar**  
Whole-time Director & CEO  
(DIN 07534225)

Place: Mumbai  
Date :12<sup>th</sup> November, 2024



**Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,

**The Board of Directors of  
Borosil Scientific Limited  
(Formerly Known as Klass Pack Limited)**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Borosil Scientific Limited (Formerly Known as Klass Pack Limited)** ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2024 ("the statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulation"), as amended.
2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Chaturvedi & Shah LLP**

Chartered Accountants

Registration No. 101720W/W100355

**Anuj Bhatia**

Partner

Membership No. 122179

UDIN No: 24122179BKFB JV2634



Place: Mumbai

Date: 12<sup>th</sup> November, 2024

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024**

(Rs. in lakhs except as stated)

S. No.	Particulars	Standalone					
		Quarter ended			Half Year ended		Year ended
		(30/09/2024)	(30/06/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(31/03/2024)
I.	<b>Income:</b>						
	Revenue From Operations	8,703.73	9,339.78	8,434.88	18,043.51	16,406.00	35,514.59
	Other Income	190.90	214.14	134.79	405.04	239.01	539.02
	<b>Total Income (I)</b>	<b>8,894.63</b>	<b>9,553.92</b>	<b>8,569.67</b>	<b>18,448.55</b>	<b>16,645.01</b>	<b>36,053.61</b>
II.	<b>Expenses:</b>						
	Cost of Materials Consumed	2,774.31	3,050.37	2,663.91	5,824.68	5,449.62	11,492.64
	Purchases of Stock-in-Trade	255.78	179.96	160.93	435.74	273.31	1,029.73
	Changes in Inventories of Work-in-progress, Finished Goods and Stock-in-trade	(242.28)	33.83	8.48	(208.45)	15.05	159.84
	Employee Benefits Expense	1,481.64	1,508.38	1,599.79	2,990.02	3,172.88	6,124.47
	Finance Costs	17.71	24.40	27.25	42.11	56.92	141.51
	Depreciation and Amortization Expense	423.44	420.06	350.24	843.50	687.22	1,506.35
	Other Expenses	3,102.10	3,471.40	2,751.22	6,573.50	5,618.20	11,600.19
	<b>Total Expenses (II)</b>	<b>7,812.70</b>	<b>8,688.40</b>	<b>7,561.82</b>	<b>16,501.10</b>	<b>15,273.20</b>	<b>32,054.73</b>
III.	<b>Profit Before Exceptional Items and Tax (I - II)</b>	<b>1,081.93</b>	<b>865.52</b>	<b>1,007.85</b>	<b>1,947.45</b>	<b>1,371.81</b>	<b>3,998.88</b>
IV.	Exceptional Items	-	-	-	-	-	-
V.	<b>Profit Before Tax (III - IV)</b>	<b>1,081.93</b>	<b>865.52</b>	<b>1,007.85</b>	<b>1,947.45</b>	<b>1,371.81</b>	<b>3,998.88</b>
VI.	<b>Tax Expense:</b>						
	(1) Current Tax	315.79	128.68	297.01	444.47	409.67	1,310.54
	(2) Deferred Tax	(2.55)	89.70	(63.59)	87.15	(231.97)	(457.59)
	<b>Total Tax Expenses</b>	<b>313.24</b>	<b>218.38</b>	<b>233.42</b>	<b>531.62</b>	<b>177.70</b>	<b>852.95</b>
VII.	<b>Profit for the Period / Year (V - VI)</b>	<b>768.69</b>	<b>647.14</b>	<b>774.43</b>	<b>1,415.83</b>	<b>1,194.11</b>	<b>3,145.93</b>
VIII.	<b>Other Comprehensive Income (OCI)</b>						
	<b>Items that will not be reclassified to profit or loss:</b>						
	a) Re-measurement gains / (losses) on defined benefit plans	(5.61)	(4.78)	(4.25)	(10.39)	(43.89)	(22.95)
	b) Income tax effect on above	1.42	1.20	1.07	2.62	11.05	5.78
	<b>Total Other Comprehensive Income</b>	<b>(4.19)</b>	<b>(3.58)</b>	<b>(3.18)</b>	<b>(7.77)</b>	<b>(32.84)</b>	<b>(17.17)</b>
IX.	<b>Total Comprehensive Income for the Period / Year (VII + VIII)</b>	<b>764.50</b>	<b>643.56</b>	<b>771.25</b>	<b>1,408.06</b>	<b>1,161.27</b>	<b>3,128.76</b>
X.	<b>Paid-up Equity Share Capital (Face value of Re. 1/- each fully paid up) (Refer Note 2)</b>	888.62	887.96	28.60	888.62	28.60	887.96
XI.	<b>Share Capital Pending Issuance (Refer Note 3)</b>	-	-	859.04	-	859.04	-
XII.	<b>Other Equity excluding Revaluation Reserve</b>						36,333.45
XIII.	<b>Earning per equity share (in Rs.) (Face value of Re. 1/- each) (Refer Note 3)</b>						
	Basic (Not Annualised)*	0.87 *	0.73 *	0.87 *	1.59 *	1.35*	3.55
	Diluted (Not Annualised)*	0.87 *	0.73 *	0.87 *	1.59 *	1.35*	3.55



# BOROSIL SCIENTIFIC LIMITED

(FORMERLY KNOWN AS KLASS PACK LIMITED)

UNAUDITED STANDALONE SEGMENT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024

(Rs. in lakhs)

S. No.	Particulars	Standalone					
		Quarter ended			Half Year ended		Year ended
		(30/09/2024)	(30/06/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(31/03/2024)
1	<b>Segment Revenue :</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	5,644.04	5,941.73	5,064.27	11,585.77	9,948.77	22,530.06
	b. Glassware	2,943.77	3,306.61	3,299.76	6,250.38	6,316.59	12,635.06
	c. Others	115.92	91.44	70.85	207.36	140.64	349.47
	<b>Total</b>	<b>8,703.73</b>	<b>9,339.78</b>	<b>8,434.88</b>	<b>18,043.51</b>	<b>16,406.00</b>	<b>35,514.59</b>
	Less : Inter Segment Revenue	-	-	-	-	-	-
	<b>Revenue from operations</b>	<b>8,703.73</b>	<b>9,339.78</b>	<b>8,434.88</b>	<b>18,043.51</b>	<b>16,406.00</b>	<b>35,514.59</b>
2	<b>Segment Results (Profit /(Loss) before tax):</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	1,738.02	1,537.63	1,124.56	3,275.65	1,924.21	5,384.21
	b. Glassware	(233.98)	(293.16)	(78.31)	(527.14)	(482.02)	(815.90)
	c. Others	69.84	35.20	26.22	105.04	49.97	144.58
	<b>Total</b>	<b>1,573.88</b>	<b>1,279.67</b>	<b>1,072.47</b>	<b>2,853.55</b>	<b>1,492.16</b>	<b>4,712.89</b>
	Less:- Finance Cost	17.71	24.40	27.25	42.11	56.92	141.51
	Less:- Other unallocable expenditure (net of income)	474.24	389.75	37.37	863.99	63.43	572.50
	<b>Profit before Tax</b>	<b>1,081.93</b>	<b>865.52</b>	<b>1,007.85</b>	<b>1,947.45</b>	<b>1,371.81</b>	<b>3,998.88</b>
3	<b>Segment Assets</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	14,994.84	14,059.69	13,340.83	14,994.84	13,340.83	14,382.31
	b. Glassware	10,867.83	11,361.26	10,240.76	10,867.83	10,240.76	11,463.54
	c. Others	220.49	190.44	282.26	220.49	282.26	280.22
	d. Un-allocated	20,945.49	21,059.91	20,051.72	20,945.49	20,051.72	21,535.70
	<b>Total</b>	<b>47,028.65</b>	<b>46,671.30</b>	<b>43,915.57</b>	<b>47,028.65</b>	<b>43,915.57</b>	<b>47,661.77</b>
4	<b>Segment Liabilities</b>						
	a. Scientific – Laboratory Glass & equipment and Process System	3,536.45	4,018.21	3,173.25	3,536.45	3,173.25	4,506.54
	b. Glassware	1,975.05	2,195.19	1,978.24	1,975.05	1,978.24	2,702.41
	c. Others	23.86	34.20	19.12	23.86	19.12	35.02
	d. Un-allocated	1,673.70	1,460.44	2,391.48	1,673.70	2,391.48	2,098.10
	<b>Total</b>	<b>7,209.06</b>	<b>7,708.04</b>	<b>7,562.09</b>	<b>7,209.06</b>	<b>7,562.09</b>	<b>9,342.07</b>

**Note :**  
The responsibility of identifying reportable segments lies with the Chief Operating Decision Maker (CODM) as per the Indian Accounting Standard 108 "Operating Segments". Considering the categories of business operations conducted and based on the future business plans, during the period, the CODM has adopted a new enhanced approach towards monitoring and allocation of the resources to the business, accordingly during the quarter and half year ended, the Company has identified two segments, namely "Scientific – Laboratory Glass & equipment and Process System" and "Glassware". The figures for the previous periods / year have been regrouped to make them comparable with those of the current period.

As per Indian Accounting Standard 108 on 'Operating Segment' (Ind-AS 108), the Company has reported "Segment information", as described below:

**Scientific – Laboratory Glass & equipment and Process System:-** Comprising of items used in laboratories, production floor and research and development

**Glassware:-** pharmaceutical primary packaging and domestic glassware items

**Others :-** Comprising of Filter Paper etc.

**Unallocated:-** Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.






**BOROSIL SCIENTIFIC LIMITED**

(FORMERLY KNOWN AS KLASSE PACK LIMITED)

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

(Rs. in lakhs)

Particulars	Standalone	
	As at	As at
	(30/09/2024)	(31/03/2024)
<b>I. ASSETS</b>		
<b>1 Non-current Assets</b>		
(a) Property, Plant and Equipment	9,218.97	9,871.93
(b) Capital work-in-progress	338.72	82.63
(c) Goodwill on Amalgamation	5,931.84	5,931.84
(d) Other Intangible assets	105.34	141.56
(e) Intangible assets under development	27.88	20.78
(f) Financial Assets		
(i) Investments	4,078.22	4,078.13
(ii) Loans	7.46	7.00
(iii) Others	158.29	154.94
(g) Non Current Tax Assets (net)	193.02	55.62
(h) Other non current assets	273.05	177.46
<b>Total non current assets</b>	<b>20,332.79</b>	<b>20,521.89</b>
<b>2 Current Assets</b>		
(a) Inventories	9,327.75	8,881.12
(b) Financial Assets		
(i) Investments	614.96	-
(ii) Trade Receivables	4,827.16	5,272.66
(iii) Cash and cash equivalents	479.48	1,180.20
(iv) Bank Balances other than (iii) above	137.62	132.74
(v) Loans	24.20	24.49
(vi) Others	9,737.68	10,322.08
(c) Other current assets	1,547.01	1,326.59
<b>Total current assets</b>	<b>26,695.86</b>	<b>27,139.88</b>
<b>TOTAL ASSETS</b>	<b>47,028.65</b>	<b>47,661.77</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	888.62	887.96
(b) Share Application Money	16.53	-
(c) Other Equity	38,914.44	37,431.74
<b>Total equity</b>	<b>39,819.59</b>	<b>38,319.70</b>
<b>LIABILITIES</b>		
<b>1 Non current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	156.32	208.92
(ii) Lease Liabilities	-	30.98
(b) Deferred Tax Liabilities (net)	828.37	743.84
<b>Total non current liabilities</b>	<b>984.69</b>	<b>983.74</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	503.80	788.88
(ii) Lease Liabilities	75.94	88.15
(iii) Trade Payables		
A) Total outstanding dues of micro and small enterprises	567.06	665.16
B) Total outstanding dues of creditors other than micro and small enterprises	1,731.11	2,891.40
(iv) Other Financial Liabilities	1,816.53	1,958.50
(b) Other current liabilities	606.54	917.77
(c) Provisions	886.22	880.69
(d) Current Tax Liabilities (net)	37.17	167.78
<b>Total current liabilities</b>	<b>6,224.37</b>	<b>8,358.33</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>47,028.65</b>	<b>47,661.77</b>



# BOROSIL SCIENTIFIC LIMITED

(FORMERLY KNOWN AS KLASSE PACK LIMITED)

UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2024

		(Rs. In Lakhs)	
Particulars		For the Half Year Ended	For the Half Year Ended
		(30/09/2024)	(30/09/2023)
<b>A. Cash Flow from Operating Activities</b>			
Profit Before Tax as per Statement of Profit and Loss		1,947.45	1,371.81
Adjusted for :			
Depreciation and Amortisation Expense		843.50	687.22
Loss / (Gain) on Foreign Currency Transactions (net)		(8.48)	(21.64)
Loss / (Gain) on Financial Instruments measured at fair value through profit or loss (net)		(1.51)	-
Loss / (Gain) on Sale of Investments (net)		(13.45)	(24.53)
Interest Income		(186.23)	(17.82)
Loss / (Gain) on Sale / discarding of Property, Plant and Equipment (net)		7.43	2.27
Share Based Payment Expense		15.31	29.41
Finance Costs		42.11	56.92
Sundry Balances / Excess Provision Written Back (net)		0.30	(0.01)
Provision / (Reversal) for Credit Impaired / Doubtful Advances (net)		(6.02)	(6.37)
<b>Operating Profit before Working Capital Changes</b>		<b>2,640.41</b>	<b>2,077.26</b>
Adjusted for :			
Trade and Other Receivables		983.21	(987.11)
Inventories		(446.63)	780.89
Trade and Other Payables		(1,687.55)	(81.56)
<b>Cash generated from / (used in) operations</b>		<b>1,489.44</b>	<b>1,789.48</b>
Direct Taxes Paid (net)		(712.48)	(690.39)
<b>Net Cash From / (Used in) Operating Activities</b>		<b>776.96</b>	<b>1,099.09</b>
<b>B. Cash Flow from Investing Activities</b>			
Purchase of Property, Plant and Equipment and Intangible Assets		(562.11)	(545.23)
Sale of Property, Plant and Equipment (net)		13.31	0.28
Investments in Subsidiary		-	(2,247.99)
Purchase of Investments		(2,600.00)	-
Sale of Investments		2,000.00	3,264.84
Loans to Subsidiary		-	(1,300.00)
Interest Income		18.26	16.16
<b>Net Cash From / (Used in) Investing Activities</b>		<b>(1,130.54)</b>	<b>(811.94)</b>
<b>C. Cash Flow from Financing Activities</b>			
Proceeds from issue of Share Capital		91.83	-
Proceeds of Non-current Borrowings		-	103.71
Repayment of Non-current Borrowings		(52.60)	(32.64)
Movement in Current Borrowings (net)		(285.08)	(4.51)
Lease Payments		(47.26)	(47.25)
Margin Money (net)		(8.03)	(3.66)
Interest Paid		(46.02)	(47.13)
<b>Net Cash From / (Used in) Financing Activities</b>		<b>(347.16)</b>	<b>(31.48)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)</b>		<b>(700.73)</b>	<b>255.67</b>
<b>Opening Balance of Cash and Cash Equivalents</b>		<b>1,180.20</b>	<b>48.92</b>
Unrealised Gain/(loss) on Foreign Currency Transactions (net)		0.04	0.08
<b>Opening Balance of Cash and Cash Equivalents</b>		<b>1,180.16</b>	<b>48.84</b>
<b>Closing Balance of Cash and Cash Equivalents</b>		<b>479.48</b>	<b>304.51</b>
Unrealised Gain/(loss) on Foreign Currency Transactions (net)		0.05	-
<b>Closing Balance of Cash and Cash Equivalents</b>		<b>479.43</b>	<b>304.51</b>





**Notes on Unaudited Standalone Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2024:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12<sup>th</sup> November, 2024. The Statutory Auditor of the Company has carried out a Limited Review of the above results.
2. Pursuant to exercise of the options issued under "Borosil Scientific Limited -Special Purpose Employee Stock Option Plan 2023", during the quarter and half year ended 30<sup>th</sup> September, 2024, the Company has made allotment of 65,791 Equity Shares of the face value of Re. 1/- each, which has resulted into increase of paid up Equity Share Capital by Rs. 0.66 lakhs and Securities Premium by Rs. 74.64 lakhs.
3. Share Capital Pending Issuance for the quarter and half year ended 30<sup>th</sup> September, 2023 represents shares to be issued to the shareholders of the Demerged Company pursuant to the Composite Scheme of Arrangement approved by the National Company Law Tribunal ("NCLT"), Mumbai vide its order dated 2<sup>nd</sup> November, 2023 ("the Scheme") and accordingly the same had been considered while calculating Earnings Per Share (EPS) as per Indian Accounting Standard (Ind AS) 33 "Earnings Per Share".
4. The figures for the corresponding previous period/year have been rearranged/regrouped wherever necessary. The figures for the quarter and half year ended 30<sup>th</sup> September, 2023 have been restated by the management pursuant to the Scheme, to make them comparable.

**For Borosil Scientific Limited  
(Formerly Known as Klass Pack Limited)**



**Vinayak Patankar**  
Whole-time Director & CEO  
(DIN 07534225)

Place: Mumbai  
Date :12<sup>th</sup> November, 2024



**BOROSIL SCIENTIFIC LIMITED (FORMERLY KNOWN AS KASS PACK LIMITED)**

CIN: L74999MH1991PLC061851

Regd. Office : 1101, 11th floor, Crescenzo, G-Block, Plot No.C-38, Opp. MCA Club, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Tel.No.(022) 67406300 Fax No.(022) 67406514 Website : www.borosilscientific.com Email : bsl@borosil.com

**EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024**

(Rs. in lakhs except as stated)

Particulars	Standalone				Consolidated			
	Quarter ended	Quarter ended	Half Year Ended	Half Year Ended	Quarter ended	Quarter ended	Half Year Ended	Half Year Ended
	(30/09/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)	(30/09/2024)	(30/09/2023)
Total income from operations	8,703.73	8,434.88	18,043.51	16,406.00	10,261.43	9,196.86	20,681.16	17,951.13
Net Profit for the period before Tax and Exceptional items	1,081.93	1,007.85	1,947.45	1,371.81	1,241.02	632.92	1,943.37	875.16
Net Profit for the period before Tax (After Exceptional items)	1,081.93	1,007.85	1,947.45	1,371.81	1,241.02	632.92	1,943.37	875.16
Net Profit for the period after Tax (After Exceptional items)	768.69	774.43	1,415.83	1,194.11	880.44	504.58	1,382.72	833.17
Total Comprehensive Income for the period (Comprising profit for the period (after tax) and other comprehensive income (after tax))	764.50	771.25	1,408.06	1,161.27	875.46	498.43	1,373.36	797.37
Equity Share Capital	888.62	28.60	888.62	28.60	888.62	28.60	888.62	28.60
Share Capital Pending Issuance	-	859.04	-	859.04	-	859.04	-	859.04
Other Equity (Excluding Revaluation Reserve as shown in the Balance Sheet)								
<b>Earning per equity share (in Rs.) (Face value of Re. 1/- each)</b>								
Basic (Not Annualised)*	0.87 *	0.87 *	1.59 *	1.35*	0.99 *	0.58 *	1.56 *	0.96 *
Diluted (Not Annualised)*	0.87 *	0.87 *	1.59 *	1.35*	0.99 *	0.58 *	1.56 *	0.96 *

1. The above is an extract of the detailed format of unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024, filed with the Stock Exchanges on 12th November, 2024 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and the Company (www.borosilscientific.com).

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th November, 2024. The Statutory Auditor of the company has carried out Limited Review of the aforesaid results.

Place : Mumbai  
Date: 12th November, 2024



**For Borosil Scientific Limited**  
(Formerly known as Klass Pack Limited)

*Vinayak Patankar*

**Vinayak Patankar**  
Whole-time Director & CEO  
(DIN 07534225)